Table 3.

Adverse Events Occurring in Patients Treated with Sorafenib

Adverse events	Any grade, n (%)	Grade 3–4, n (%)	Withdrawal, n (%)
Any treatment-related adverse effect	93 (95)	40 (41)	13 (13)
Hand-foot skin reaction	74 (76)	20 (20)	3 (3)
Diarrhea	46 (47)	1 (1)	0
Alopecia	30 (31)	0	0
Rash or desquamation	32 (33)	3 (3)	0
Mucositis	26 (27)	3 (3)	0
Hypertension	31 (32)	2 (2)	0
Abdominal pain	2 (2)	0	0
Hemoptysis	3 (3)	1 (1)	1 (1)
General weakness	29 (30)	7 (7)	2 (2)
Headache	2 (2)	0	0
Neutropenia	3 (3)	1 (1)	1 (1)
Tracheoesophageal fistula	1 (1)	1 (1)	1 (1)
Empyema	1 (1)	1 (1)	1 (1)
Anorexia/nausea	7 (7)	1 (1)	0
Secondary malignancy	2 (2)	2 (2)	2 (2)
Constipation	1 (1)	0	0
Dyspnea	2 (2)	0	0
Dizziness	1 (1)	0	0
Decreased weight	1 (1)	0	0
Acute pancreatitis	1 (1)	1 (1)	1 (1)
Increased aspartate aminotransferase	2 (2)	2 (2)	1 (1)

Adverse events were classified with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0.